ASTX660 is primarily investigated for its potential in cancer therapy. It functions as an inhibitor of cellular inhibitor of apoptosis proteins (cIAPs), which are often overexpressed in various cancers, contributing to tumor survival and resistance to treatment. By targeting cIAPs, ASTX660 promotes cancer cell death and enhances the effectiveness of other anticancer therapies. It is being explored in clinical trials for its ability to treat solid tumors and hematologic malignancies, offering a promising approach to overcoming drug resistance in cancer patients. Its application could significantly improve outcomes in cancers that are difficult to treat with conventional methods.